MedPath

Effect Of Dantyadi Kashaya Yoni Prakshalana in Shweta Pradara with special reference to Candida vaginitis

Phase 3
Not yet recruiting
Conditions
Candidiasis of vulva and vagina. Ayurveda Condition: SLAISHMIKA-ASRUGDARAH,
Registration Number
CTRI/2023/10/059311
Lead Sponsor
Dr Nikita M Magennavar
Brief Summary

·      Abnormal vaginaldischarge is a frequent complaint of women seen in the gynecologic clinic. Thedischarge may range from excess of normal to one which is a part of widespectrum of diseases. Candidavaginitis is caused by *Candida albicans* a gram - positive yeast like fungus. The patientcomplains of vaginal discharge with intense vulvovaginal pruritis. In *Ayurveda,* the word *Shwetapradara* has not appeared in the *BruhatTrayis.* Commentator *Chakrapani,*and *Samhitas* like *Sharangadhra Samhita* have used the word *Shweta Pradara* for white vaginalDischarges. Though *Kaphadosha* involvementis directly not mentioned but the characteristic clinical feature like *Sneha, Sheeta, Shukla*, *Drava* etc are that of *Kapha* thus *Shweta Pradara* is a *Kaphaja Vyadhi*.Since the pruritis is out of proportion to discharge this can be correlated toCandida vaginitis.

·      *Panchavalkala Kashaya* has been taken as standard drug and the combinationof *Guduchi*, *Triphala* and *Danti (Dantyadi) Kashaya* is takenas trial drug as *Dantyadi Kashay*a contains the drugs that are mainly *Tridoshahara,Krumighna, Vishaghna & Vedanasthapana*. Here is an attempt to see andcompare the effect of these formulations in management of *Shweta Pradara*(Candida vaginitis).

·      This is a randomized comparativeclinical study. Total 40 patients of *Shweta pradara* who fulfills theInclusion Criteria and having Classical sign and symptoms of *Shweta pradara* willbe selected from the OPD and Medical camps conducted by SDM Trust’s PadmaAyurvedic Hospital and Research Centre, Terdal. These patients are randomlydivided into two groups A and B. Group A will be given *Dantyadi Kashaya yoniprakshalana*and Group B given *Panchavalkala Kashayayoniprakshalana*. Consent will be taken from patient andCase details will be recorded in separate case report form (CRF).  Total Study duration will be 30 days and contain9 visits (0th– 7thday, 15th day, 30thday), which includes administration of trial drug for 7days and post medicationfollow up on 15th& 30th day. After study, data willbe collected from case report form (CRF) and statistically analysed by usingappropriate parametric and nonparametrictests and results will be obtained. Onthat basis of results, conclusion will be drawn.

·

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria

•Patients with Pratyatma Lakshana’s of Shweta Pradara tested positive for presence of Candida albicans through Wet Mount Microscopy •Married women •Subjects willing to sign the consent form.

Exclusion Criteria
  • •Diagnosed case of PCOD, PID, UTI •Patients with Systemic disorders like HTN, DM •K/C/O Congenital abnormalities.
  • •K/C/O Thyroid and Parathyroid diseases, Malignancy •Copper T and OCP using women, Pregnant and Lactating women •K/C/O Cervical Erosion, Cervicitis •K/C/O HIV, Hepatitis B, STD’s.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effect of trial drug in classical symptoms of Shweta Pradara w.s.r to Candida Vaginitis i.e.,15th day, 30th day
2.Yonikandu(Itching).15th day, 30th day
1.Srava(whiteDischarge).15th day, 30th day
3. Daurgandhya(FoulSmell).15th day, 30th day
4.Kati shoola(Backache).15th day, 30th day
5.Yoni vedana15th day, 30th day
Secondary Outcome Measures
NameTimeMethod
Safety of trial drug, adverse reaction & aggravation of symptoms of Shweta Pradara w.s.r Candida vaginitis1st to 7th day

Trial Locations

Locations (1)

Padma Ayurvedic Hospital And Research Centre

🇮🇳

Bagalkot, KARNATAKA, India

Padma Ayurvedic Hospital And Research Centre
🇮🇳Bagalkot, KARNATAKA, India
Dr Nikita M Magennavar
Principal investigator
8861915770
13.nikitam@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.